Evidence map›Paper›PMID 34803761›Full record

ArticleFrontiers in psychiatry2021

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.

Martin L Williams, Diana Korevaar, Renee Harvey, Paul B Fitzgerald, Paul Liknaitzky, Sean O'Carroll, Prashanth Puspanathan, Margaret Ross, Nigel Strauss, James Bennett-Levy

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Social network reductions are associated with negative symptoms in schizophrenia.Social psychiatry and psychiatric epidemiology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martin L WilliamsTurner Institute, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia.
Diana KorevaarDepartment of Psychosocial Cancer Care & Palliative Care, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Renee HarveyMillswyn Clinic, Melbourne, VIC, Australia.
Paul B FitzgeraldEpworth Centre for Innovation in Mental Health, Epworth Healthcare, Melbourne, VIC, Australia.
Paul LiknaitzkyTurner Institute, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia.
Sean O'CarrollWild Mind Institute, Melbourne, VIC, Australia.
Prashanth PuspanathanEnosis Therapeutics, Melbourne, VIC, Australia.
Margaret RossDepartment of Psychosocial Cancer Care & Palliative Care, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Nigel StraussDepartment of Psychosocial Cancer Care & Palliative Care, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
James Bennett-LevyUniversity Centre for Rural Health, The University of Sydney, Lismore, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research exploring the potential of psychedelic-assisted therapies to treat a range of mental illnesses is flourishing, after the problematic sociopolitical history of psychedelics led to the shutdown of clinical research for almost 40 years. Encouraged by positive results, clinicians and patients are now hopeful that further interruptions to research will be avoided, so that the early promise of these therapies might be fulfilled. At this early stage of renewed interest, researchers are understandably focusing more on clinical trials to investigate safety and efficacy, than on longer-term goals such as progression to community practice. Looking to identify and avoid potential pitfalls on the path to community clinics, the authors, a group of Australian clinicians and researchers, met to discuss possible obstacles. Five broad categories of challenge were identified: 1) inherent risks; 2) poor clinical practice; 3) inadequate infrastructure; 4) problematic perceptions; and 5) divisive relationships and fractionation of the field. Our analysis led us to propose some strategies, including public sector support of research and training to establish best practice and optimize translation, and funding to address issues of equitable access to treatment. Above all, we believe that strategic planning and professional cohesion will be crucial for success. Accordingly, our key recommendation is the establishment of a multidisciplinary advisory body, broadly endorsed and representing all major stakeholders, to guide policy and implementation of psychedelic-assisted therapies in Australia. Although these challenges and strategies are framed within the Australian context, we sense that they may generalize to other parts of the world. Wherever they apply, we believe that anticipation of potential difficulties, and creative responses to address them, will be important to avoid roadblocks in the future and keep the "psychedelic renaissance" on track.

Indexed as

clinical researchcommunity clinicsdepressionmental healthpsilocybinpsychedelicstranslationtrauma

Identifiers

PMID34803761
PMCPMC8599345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.